Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Australia, Brazil, United Kingdom, Europe, Canada
The Other Vaccines market in Southern Europe has been experiencing steady growth in recent years.
Customer preferences: Customers in Southern Europe have been increasingly concerned about their health and well-being, leading to a greater demand for vaccines. The COVID-19 pandemic has also raised awareness about the importance of vaccines and their role in preventing the spread of infectious diseases.
Trends in the market: One of the key trends in the Other Vaccines market in Southern Europe is the increasing adoption of new vaccines. Pharmaceutical companies are investing heavily in research and development to create new and more effective vaccines, and customers are willing to pay a premium for these products. Another trend is the growing popularity of combination vaccines, which offer protection against multiple diseases in a single shot.
Local special circumstances: Southern Europe has a large population of elderly people, who are more susceptible to diseases and require more vaccines. In addition, the region has a high incidence of certain diseases, such as hepatitis B and C, which has led to a greater demand for vaccines against these diseases. Finally, Southern Europe is a popular tourist destination, which has increased the risk of infectious diseases being brought into the region.
Underlying macroeconomic factors: The Other Vaccines market in Southern Europe is driven by a number of macroeconomic factors. These include increasing healthcare spending, rising disposable incomes, and government initiatives to promote vaccination. In addition, the region's aging population and high incidence of certain diseases have created a favorable market environment for vaccine manufacturers. Finally, the COVID-19 pandemic has highlighted the importance of vaccines and is likely to drive further growth in the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)